AI brief of an SEC Form 8-K · Roivant Sciences (ROIV)

Roivant swings to $273.9 million loss from continuing operations in quarter ended June 30

Negative Impact 3 of 5 earnings Written later

Roivant reported a loss from continuing operations of $273.9 million for the quarter ended June 30, 2025, compared with income of $31.6 million a year earlier, or $0.33 loss per share versus $0.01 income per share. Revenue fell to $2.2 million from $8.0 million, while research and development and general and administrative expenses rose, and share-based compensation increased sharply.

Key points

  • Revenue was $2.2 million versus $8.0 million in the prior-year quarter
  • Research and development expenses rose $32.4 million to $152.9 million; general and administrative expenses rose $34.1 million to $134.0 million
  • Share-based compensation in general and administrative expenses was $71.1 million versus $36.8 million
  • Cash, cash equivalents, restricted cash and marketable securities were $4.5 billion at June 30, 2025; a new $500 million buyback was approved in June 2025

The filing

CompanyRoivant Sciences (ROIV)
Form8-K, current report
Filed with the SECAug 11, 2025, 7:17 AM ET
Accession number0001140361-25-029998

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.